SlideShare una empresa de Scribd logo
1 de 54
Descargar para leer sin conexión
Federal Food, Drug & Cosmetics Act
Kefauver's-Harris Amendments




                     ABDUL MUHEEM
                     M.PHARMA 2ND SEM.
                     (PHARMACEUTICS)
                     JAMIA HAMADARD
                     muheem.abdul985@gmail.com
Federal food, drug & cosmetics act
OBJECTIVES OF FFDCA
In     United     States     Federal     Food,    Drug,     and      Cosmetic
Act (FFDCA, FDCA, or FD&C), is a set of laws passed by Congress in 1938 giving
authority to the U.S. Food and Drug Administration (FDA) to oversee the safety
of food, drugs, and cosmetics.
 It replaced the earlier Pure Food and Drug Act of 1906 due to Elixir
    Sulphanilamide disaster.
 1938 Act continued the information provision requirements of
  the 1906 Act. The classification “misbranded” was expanded
  example, and now included any drug whose label failed to
  identify and quantify the precise ingredients, to list effects
  and possible side effects, and to give directions and
  cautionary information.
 1938 Act also expanded the FDA’s powers over medical
   devices .
Federal food, drug & cosmetics act
Reason for implemented new act
 1937 – sulfanilamide crisis


                        November            16,           1937:
                        A Senate resolution directs the U.S.
                        Department of Agriculture to give a
                        full   accounting    of    the    "Elixir
                        Sulfanilamide"       tragedy.       The
                        drug,    containing     a     poisonous
                        solvent(ethylene glycol / propylene
                        glycol mix-up), was not safety tested
                        and has killed 107 persons, many of
                        them children. The incident made
                        Congress    to   pass     the   Federal
                        Food, Drug, and Cosmetic Act, which
                        includes    stronger     drug     safety
                        requirements
OTHER TRAGEDIES
Koremlu Cream
Contained Thallium acetate
Serious hazardous side effects due to thallium
Radiothor
"Radium containing water“
Consumers died of radiation exposure
Label true and no therapeutic claims
   Lack of standards for food products
 Developments in Science and technology
    Canning / Chemical analysis
 Expansion of cosmetics industry
GOALS OF FDCA(1938)
 The FDCA mandates the safety, purity, and in some cases the
  "effectiveness" of the products within its scope.
 FDA ensures safety through inspections of products already on
  the market, controls the manufacturing practices of
  companies, and possesses recall and seizure authority.
 The FDCA's Goal is to disclose information- requires
  truthfulness and completeness in product labeling and other
  marketing communications.
 The act forbids "misbranding," and provides a range of civil and
  criminal enforcement mechanisms against inaccurate product
  labeling.
 Section contains both civil law and criminal law clauses.
 The FDCA in 1958 with the Food Additives Amendment (also
  called the "Delaney Clause" after its House sponsor), precluding
  FDA approval of any food additive found to cause cancer in
  humans or animals.
Food & drug act
 Prohibited the sales of adulterated &misbranded drugs.
 Drug could be marketed as long as the label did not present
  false information regarding the strength & purity.
 no requirement to disclose ingredients.
 A largely unregulated industry was causing numerous public
  health problems.
Federal food, drug & cosmetics act
CHAPTER WISE DESCRIPTION:
Chapter I. Short Titles
Chapter II – Definitions.
 201(f) is the definition for a food, which explicitly includes chewing
  gum
 201(g) is the definition for a drug
 201(h) is the definition for a medical device
 201(s) is the definition of a food additive
 201(ff) is the definition of a dietary supplement
CHAPTER III. Prohibited Acts and Penalties


  301. Prohibited Acts
   302. Injunction proceedings
   303. Penalties
   304. Seizures
   305. Hearing before report of criminal violation
   306. Report of minor violations
   307. Proceedings in name of United States; provision as to
   subpoenas .
CHAPTER IV. Food
  401. Definitions and standards for food
  402. Adulterated food
  403. Misbranded food
  404. Emergency permit control
  405. Regulations making exemptions
  406. Tolerances for poisonous ingredients in food
  407. Oleomargarine or margarine
  408. Tolerances for pesticide chemicals in or
  on raw agricultural commodities
  409. Food additives
  410. Bottled drinking water
  411. Vitamins and minerals
  412. Requirements for Infant Formulas .
CHAPTER V. Drugs and Devices


 505 is the description of the drug approval process
 510(k) is the section that allows for clearance of medical devices
 515 is the description of the device approval process.
DRUG AND DEVICES
Sections in FDCA gives following information-
 505 is the description of the drug approval process
 510(k) is the section that allows for clearance of class II medical
  devices
 515 is the description of the (class III) device approval process.
Section 510(k) of the Federal Food, Drug, and Cosmetic Act requires
  those device manufacturers who must register to notify FDA, at least
  90 days in advance, of their intent to market a medical device. This is
  known as Premarket Notification.
Class I: Devices that do not require premarket approval or clearance but
   must follow general controls. Dental floss is a class I device.
Class II: Devices that are cleared using the 510(k) process. Diagnostic
   tests, cardiac catheters, and amalgam alloys used to fill cavities are
   all class II devices.
Class III: Devices that are approved by the Premarket Approval (PMA)
   process, analogous to a New Drug Application. These tend to be
   devices that are permanently implanted into a human body or may be
   necessary to sustain life
CHAPTER VII :


GENERAL ADMINISTRATIVE PROVISIONS


 701. Regulations and hearings
 702. Examinations and investigations
 702a. Seafood inspection
 703. Records of interstate shipment
 704. Factory inspection
 705. Publicity
 706. Listing and certification of color additives for foods, drugs, and
 cosmetics.
CHAPTER VIII :
        801.Imports And Exports 8


CHAPTER IX :
       901. Miscellaneous
LIMITATIONS OF 1938,FOOD DRUG
AND COSMETIC ACT INCLUDES
 It   did not included drugs which were previously
  marketed.
 Drugs had to be proven safe but        not   proven
  effective.
 The federal govt. had little authority to enact
  penalties, if the information on the labels was not
  written clearly.
 Drugs manufacturer were given the responsibility for
  determining whether a drug would be sold as a
  prescription or over the counter drug.
 Drug manufacturers conducted their own test to
  determine drugs effectiveness.
Federal food, drug & cosmetics act
Introduction
 The Food and Drug Administration (FDA),
  established in 1938 as a part of the US Department
  of Health and Human Services (HHS), regulates
  products accounting for roughly 25% of the US gross
  national product.
 Major concerns arose with the scandal of birth
  defects    in   European    nations    caused    by
  Thalidomide, a drug to be introduced into the US.
 The drug was already in use by the pregnant women
  in Africa and Europe from 1956-1962 and caused an
  estimated 10,000 children born with congenital
  deformitiesPhocomelia.).
IMPORTANT ACT &
AMENDMENTS
News & Implementation Of
   Amendments
Week In FDA History - July
             15,1962
Thalidomide, a newly developed
sleeping pill, is found to have
caused      birth    defects    in
thousands of babies born in
Western Europe. News reports
on the role of FDA medical
officer Dr. Frances O. Kelsey in
keeping the drug off the
American market arouse public
support     for   stronger   drug
regulation
Week In FDA History - Oct. 10,1962
 October     10,     1962:
  The       Kefauver-Harris
  Drug Amendments are
  passed, prompted in part
  by public concern over
  birth defects caused by
  the drug thalidomide.
  Among        the      new
  requirements: proof of
  drug effectiveness as
  well as safety, controls
  over clinical trials, and
  better quality assurance
  practices     in     drug
  manufacturing
 Dr. Francis Kathleen Oldham Kelsey, working for the US FDA
  did not want to approve thalidomide into the American drug
  market because it was not properly tested as a result of what
  was going on in those years.
 The KEFAUVER HARRIS AMENDMENT was a response to the
  thalidomide tragedy. It was signed by President John F.
  Kennedy on October 10, 1962.
 US senator Estes Kefauver of the state of Tennessee and
  Arkansas state representative Oren Harris required the
  American drug manufacturers to present proof of the safety and
  effectiveness of their drugs before any endorsements.
 Hence, this amendment is also referred to as the DRUG
  EFFICACY AMENDMENT.
Federal food, drug & cosmetics act
KEFAUVER HARRIS
AMENDMENT


I
N
T
                Concerne      Controls
R                             over clinical
O               d     with
                              trials   and
D               proof    of
    Passed in                 better    QA
U               drug
      1962                    practices in
C               effectiven    drug
T               ess    and    manufacturi
I               safety        ng
O
N
Objectives Of Amendments
 Efficacy was to be established for all drugs since
  1938.
 Required FDA to assess the efficacy as well as
  safety for all drugs products.
 First time manufactures were required to prove
  effectiveness of drug products prior to marketing.
 Gave FDA stricter control over clinical drug trials.
 Set GMP to be followed by drug industry.
 Regulated advertising.
 Kefauver-Harris imposed the efficacy requirement
  prior to NDA approval by FDA.
APPROVAL OF NEW DRUGS AFTER
IMPLEMENTED OF AMENDMENTS


 New drug:
     1) safe and effective.
      2) approved under NDA procedure a/c
  to act at section 505.
 IND: for filing IND, form FD-1571,FD-
 1572 and FD-1573 are filled.
 NDA: Form FD-356.
Federal food, drug & cosmetics act
DRUG EFFICACY STUDy
IMPLEMENTATION (DESI)



 COLLABORATION
 WITH   NATIONAL                    ESTABLISHME
 ACADEMY       OF                   NT OF THE
 SCIENCE-                           DESI
 NATIONAL                           PROGRAM IN
 RESEARCH                           1968
 COUNCIL     (NAS-
 NRC)

 It was a retrospective efficacy assessment of drugs
 approved prior to 1962.
DRUG EFFICACY STUDIES
  Early development
In 1966, FDA commissioner approached NAS-NRC to review
already marketed drugs under NDAs approved from 1938-1962.
There were about 300 different medicinal agents.



 This was carried out by establishing review committees and a
 Policy Advisory Committee whose members were well
 acquainted with medical, legal and industrial problems of drugs.



27 and more panels were developed concerning with drugs used
in allergy, anti histaminics, dermatology, anti neoplastics, etc.
Guidelines were established by the advisory committee to review
work of the panels.



By October 1969, the review program was formerly organized and
in operation. The types of products reviewed included single drug
entities or products with two or more entities.
DRUG EFFICACY STUDIES
         Early development

The panels sought evidence of drug efficacy
from four main sources:

  1) Briefs submitted by the sponsor of the drug
  2)Additional evidence directly solicited from the
  sponsor
  3)The files of the FDA
  4)Pertinent medical literature brought in by the
  panelists.
DRUG EFFICACY STUDIES
Effectiveness
categories


                          EFFECTIVE
                          Substantial
                          evidence of
                            efficacy



                          INEFFECTI
                             VE
                          Insufficient
                              data
                          supporting
                            efficacy
           PROBABLY                      POSSIBLY
           EFFECTIVE                     EFFECTIVE
             Needed                       Research
            extra info,                  needed, max
           max time 12                      time 6
             months                        months
DRUG EFFICACY STUDIES
The conclusions

      IMMEDIATE REMOVAL    OF   PRODUCTS
      CURRENTLY MARKETED

      RECOGNITION OF CLINICAL STUDIES TO
      VERIFY OR ESTABLISH EFFECTIVENESS
      UNDER THE NEW LAW

     RECOGNITION THAT DIRECTION OR
     LABELLING OF CERTAIN PRODUCTS WERE
     POORLY ORGANIZED, OUTDATED AND
     ORIENTED TO PROMOTION OF PRODUCT
     PACKAGE INSERTS NEEDED TO BE
     BROUGHT UP TO MODERN STANDARDS
     OF ACCURATE AND OBJECTIVE DRUG
     INFORMATION.
DRUG EFFICACY STUDY
            RECORDS
The records of the Drug Efficacy
  Study contains:

 Correspondence

 reports

 meeting minutes

 press clippings

 other records documenting the
  activities of the DES.
DRUG EFFICACY STUDIES
 abbreviated new drug applications
 One of the early effects        of   DESI   study   was   the
  development of ANDA.
 An Abbreviated New Drug Application (ANDA) is an
  application for a U.S. generic drug approval for an existing
  licensed medication or approved drug.
 The ANDA is submitted to FDA's Center for Drug
  Evaluation and Research, Office of Generic Drugs, which
  provides for the review and ultimate approval of a generic
  drug product. Once approved, an applicant may
  manufacture and market the generic drug product to
  provide a safe, effective, low cost alternative to the
  American public.
 A generic drug product is one that is comparable to an
  innovator drug product in dosage form, strength, route of
  administration, quality, performance characteristics and
  intended use. All approved products, both innovator and
  generic, are listed in FDA's Approved Drug Products
  with Therapeutic Equivalence Evaluations.
DRUG EFFICACY STUDIES
 abbreviated new drug applications
 Generic drug applications are termed "abbreviated"
  because they are generally not required to include
  preclinical (animal) and clinical (human) data to establish
  safety and effectiveness. Instead, generic applicants must
  scientifically  demonstrate      that  their  product     is
  bioequivalent (i.e., performs in the same manner as the
  innovator drug).
 The generic version must deliver the same amount of
  active ingredients into a patient's bloodstream in the same
  amount of time as the innovator drug.
 Using bioequivalence as the basis for approving generic
  copies of drug products was established by the Drug Price
  Competition and Patent Term Restoration Act of
  1984, also known as the HATCH-WAXMAN ACT.
 This Act expedites the availability of less costly generic
  drugs by permitting FDA to approve applications to market
  generic versions of brand-name drugs without conducting
  costly and duplicative clinical trials.
Federal food, drug & cosmetics act
FLUOROQU
 INOLONE
                THE BLACK BOX
Tendonitis
 (8 july,
                REGULATION
  2008)         On 12 Feb. 1972 FDA promulgated this regulation which
                 required that the “less than effective” products should be
 AVANDIA         notified to the practitioner’s by including a statement
    (anti        prominently in the labeling & surrounding it with an
  diabetic)      appropriate border.
Heart attack
     14
Nov, 2007
                It is a type of warning that appears on the package insert
   DEPO          for prescription drugs that may cause serious adverse
 PROVERA         effects. It is so named for the black border that usually
Loss of bone     surrounds the text of the warning.
  density
  17 Nov,
   2004         It is the strongest warning that the FDA requires.
CELEBREX
(celecoxib)
  CV & GI
    risk
   2002
THE BLACK BOX
REGULATION
Other FDA REASSESSMENT
PROJECTS
    The GRAS List Review of 1969
     (review of the safety of all the
     food ingredients that had been
     included   on    the     Generally
     Recognized As Safe List of the late
     1950s);
    The OTC Drug Review of 1972
     (review of the safety and efficacy
     of all OTC drugs; and
    The Biologics Review of 1972
     (review the safety and efficacy of
     all biologicals)
Federal food, drug & cosmetics act
Other related
legislations
       The     Medical   Device
       Amendments of 1976
       followed a U.S. Senate
       finding     that    faulty
       medical    devices    had
       caused 10,000 injuries,
       including 731 deaths. The
       law applied safety and
       effectiveness safeguards
       to new devices.
Other related
legislations

              2005
 Formation of the Drug Safety
 Board consisting of FDA staff
 and representatives from the
 National Institutes of Health and
 the Veterans Administration.
 The Board will advise the
 Director,   Center     for   Drug
 Evaluation and Research, FDA,
 on drug safety issues.
Contd…
 DRUG SAFETY AND DRUG EFFICACY:
   TWO SIDES OF THE SAME COIN

 In 2007, a committee of academic
 scientists,    research   advocates    and
 representatives of patient community
 was convened to recommend ways in
 which the Congress and the FDA could
 further strengthen product evaluation for
 it’s efficacy.
 A similar article was also published in the
 AACR, in the same year.
SAFETY AND EFFICACY
         MONITORING
         Current scenario

                                       FDA’s
                                       MedWatch
                                       program can
                   Serious        &    also be
                   unexpected          approached
                   side     effects    for this
NDA sponsors       should write to     purpose.
submit reports     the FDA within
quarterly    for   15    days     of
first 3 yrs and    receipt of info.
annually
afterwards.
Impacts of Kefauver Harris
Amendment(1962)
• The Kefauver Harris Amendment strengthened the U.S.
  Food and Drug Administration's control of
  experimentation on humans.
• It changed the way new drugs are approved and
  regulated.
• It introduced a "proof-of-efficacy" requirement, that
  was not present before.
• The Amendment required drug advertising to disclose
  accurate information about side effects and efficacy of
  treatments.
• Cheap generic drugs could no longer be marketed as
  expensive drugs under new trade names as new
  "breakthrough" medications, as they were prior to the
  amendment
Federal food, drug & cosmetics act
DRUG EFFICACY STUDY IMPLEMENTATION

The amendment made onerous to evaluate each
product, also to evaluate the active ingredients in
the products. The active ingredients were placed
into one of the three categories.
Category I drugs: those determined to be safe ,
effective, and properly labeled.
Category II drugs:          those not generally
recognized as safe and effective, or recognized as
mislabeled; must be removed from medications
within 6 months after the FDA issues its final
regulations.
Category III drugs: those for which data is
insufficient to determine general recognition of
safety and effectiveness.
CONCLUSION
Today, the FDA regulates $1 trillion worth
of products a year. It ensures the safety of
all food except for meat, poultry and some
egg products; ensures the safety and
effectiveness of all drugs, biological
products (including blood, vaccines and
tissues    for  transplantation),   medical
devices, and animal drugs and feed; and
makes sure that cosmetics and medical
and consumer products that emit radiation
do no harm.
ConClusions …




By 1984, final action had been completed on 3,443
products; - 2,225 were found to be effective, 1,051
were found not effective, and 167 were pending.
References
 http://www.absoluteastronomy.com/discussion/Drug_Efficacy_Stu
  dy_Implementation
 http://en.wikipedia.org/wiki/Talk:Drug_Efficacy_Study_Implement
  ation
 http://www.ssa.gov/OP_Home/comp2/B-CFR-42.html
 http://www.nationalacademies.org/ The Drug Efficacy Study of the
  National Research Council’s Division of Medical Sciences, 1966-
  1969,
 W.M. WARDELL, The US Drug Efficacy Study and its Implication
  (DESI), Associate Professor, Pharmacology and Toxicology,
  University of Rochester, and Director, Center for the Study of Drug
  Development, USA
 http://edocket.access.gpo.gov/cfr_2008/aprqtr/pdf/21cfr207.20.p
  df
 W.E. GILBERTSON, The OCT Drug Review - FDA's Viewpoint,
  Director Division of OTC Drug Evaluation, Food and Drug
  Administration, Rockville, Maryland, USA
 Julie B. Esmay, B.S., and Albert I. Wertheimer, Ph.D., A REVIEW OF
  OVER-THE-COUNTER DRUG THERAPY, Journal of Community Health
  Vol. 5, No. 1, Fall 1979,
References
 Http://www.Personalcarecouncil.Org/
 Http://www.Fda.Gov/drugs/informationondrugs/default.Htm
 Http://www.Fda.Gov/drugs/guidancecomplianceregulatoryin
  formation/drugregistrationandlisting/default.Htm
 Center for veterinary medicine program policy and
  procedures manual, guide 1240.3560, General review and
  enforcement     policies,  responsible  office:   hfv-210,
  registration of producers of drugs and listing of drugs in
  commercial distribution.
 Guidance for industry , providing regulatory submissions in
 electronic format – drug establishment registration and drug
 listing
 Alan h. Kaplan, esq., Fifty years of drug amendments
  revisited: in easy-to-swallow capsule form
Federal food, drug & cosmetics act

Más contenido relacionado

La actualidad más candente

Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsMichael Swit
 
INSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSINSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSOORATHI SASIVARDHAN
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Aakashdeep Raval
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union ShantanuThakre3
 
Post Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCsPost Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCsDr. Reena Malik
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxNikhilBorade5
 
Regulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesRegulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesAtul Bhombe
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYdatchayani
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESVikas Rathee
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory PracticesSwapnil Fernandes
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPTDoninder Hooda
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]siddharthchachad
 
Drug Regulatory Systems in India
Drug Regulatory Systems in IndiaDrug Regulatory Systems in India
Drug Regulatory Systems in IndiaChandra Mohan
 
labelling of drugs and cosmetics in European Union
labelling of drugs and cosmetics in European Unionlabelling of drugs and cosmetics in European Union
labelling of drugs and cosmetics in European UnionBindu Kshtriya
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaDr. Pankaj Bablani
 
Premarket Notification 510(k) for Biologics [Autosaved].pptx
Premarket Notification 510(k) for Biologics [Autosaved].pptxPremarket Notification 510(k) for Biologics [Autosaved].pptx
Premarket Notification 510(k) for Biologics [Autosaved].pptxSusmithaTella2
 

La actualidad más candente (20)

Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement ActionsLabeling/Advertising and Promotion, Import/Export, and Enforcement Actions
Labeling/Advertising and Promotion, Import/Export, and Enforcement Actions
 
INSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELSINSPECTION OF DRUG DISTRIBUTION CHANNELS
INSPECTION OF DRUG DISTRIBUTION CHANNELS
 
Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.Comparison of Clinical Trial Application requirement of India, USA and Europe.
Comparison of Clinical Trial Application requirement of India, USA and Europe.
 
Clinical Research Regulation in European Union
Clinical Research Regulation in European Union Clinical Research Regulation in European Union
Clinical Research Regulation in European Union
 
Post Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCsPost Marketing Requirements/Complaince: PMRs and PMCs
Post Marketing Requirements/Complaince: PMRs and PMCs
 
European_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptxEuropean_Union.ppt.Nikhil[1].pptx
European_Union.ppt.Nikhil[1].pptx
 
Regulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devicesRegulatory requirement and approval procedure for medical devices
Regulatory requirement and approval procedure for medical devices
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
GHTF
GHTFGHTF
GHTF
 
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIESREGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
REGULATORY REQUIREMENTS FOR ASEAN COUNTRIES
 
Regulatory requirements for orphan drugs delivery
Regulatory requirements for orphan drugs deliveryRegulatory requirements for orphan drugs delivery
Regulatory requirements for orphan drugs delivery
 
Good Automated Laboratory Practices
Good Automated Laboratory PracticesGood Automated Laboratory Practices
Good Automated Laboratory Practices
 
Electronic submission PPT
Electronic submission PPTElectronic submission PPT
Electronic submission PPT
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]
 
GHTF study group 3
GHTF study group 3GHTF study group 3
GHTF study group 3
 
Overview of the FDA
Overview of the FDAOverview of the FDA
Overview of the FDA
 
Drug Regulatory Systems in India
Drug Regulatory Systems in IndiaDrug Regulatory Systems in India
Drug Regulatory Systems in India
 
labelling of drugs and cosmetics in European Union
labelling of drugs and cosmetics in European Unionlabelling of drugs and cosmetics in European Union
labelling of drugs and cosmetics in European Union
 
Regulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & IndiaRegulations for drug approval in USA, E.U & India
Regulations for drug approval in USA, E.U & India
 
Premarket Notification 510(k) for Biologics [Autosaved].pptx
Premarket Notification 510(k) for Biologics [Autosaved].pptxPremarket Notification 510(k) for Biologics [Autosaved].pptx
Premarket Notification 510(k) for Biologics [Autosaved].pptx
 

Destacado (20)

The drug and cosmetic act and rules
The drug and cosmetic act and rulesThe drug and cosmetic act and rules
The drug and cosmetic act and rules
 
Drugs & cosmetics act 1940
Drugs & cosmetics act 1940Drugs & cosmetics act 1940
Drugs & cosmetics act 1940
 
Achyutha anda
Achyutha andaAchyutha anda
Achyutha anda
 
List of Impurities 231015
List of Impurities 231015List of Impurities 231015
List of Impurities 231015
 
IIMPORT AND REGISTRATION AS PER DRUG AND COSMETIC ACT
IIMPORT AND REGISTRATION AS PER  DRUG AND COSMETIC ACT IIMPORT AND REGISTRATION AS PER  DRUG AND COSMETIC ACT
IIMPORT AND REGISTRATION AS PER DRUG AND COSMETIC ACT
 
Historical aspects of drug approval process
Historical aspects of drug approval processHistorical aspects of drug approval process
Historical aspects of drug approval process
 
Who
WhoWho
Who
 
Optimization in pharmaceutics & processing
Optimization in pharmaceutics & processingOptimization in pharmaceutics & processing
Optimization in pharmaceutics & processing
 
Packaging designs and specifications
Packaging designs and specificationsPackaging designs and specifications
Packaging designs and specifications
 
Optimization in pharmaceutics & processing
Optimization in pharmaceutics & processingOptimization in pharmaceutics & processing
Optimization in pharmaceutics & processing
 
Drug design intro
Drug design introDrug design intro
Drug design intro
 
Validation03
Validation03Validation03
Validation03
 
2 genomes
2 genomes2 genomes
2 genomes
 
Bio info statistical-methods[1]
Bio info statistical-methods[1]Bio info statistical-methods[1]
Bio info statistical-methods[1]
 
Who
WhoWho
Who
 
1 amino acids
1 amino acids1 amino acids
1 amino acids
 
What is glp
What is glpWhat is glp
What is glp
 
Wto scope introd
Wto scope introdWto scope introd
Wto scope introd
 
Validation of water supply system
Validation of water supply systemValidation of water supply system
Validation of water supply system
 
Penetration enhencers
Penetration enhencersPenetration enhencers
Penetration enhencers
 

Similar a Federal food, drug & cosmetics act

History of Drug Aproval
History of Drug AprovalHistory of Drug Aproval
History of Drug Aprovaldbwalton
 
Drug development and nda
Drug development and ndaDrug development and nda
Drug development and ndaGaurav Kr
 
73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docxalinainglis
 
Food And Drug Administration V Brown &Amp; Williamson
Food And Drug Administration V Brown &Amp; WilliamsonFood And Drug Administration V Brown &Amp; Williamson
Food And Drug Administration V Brown &Amp; WilliamsonMarie Smith
 
Food and Drugs Administration.pptx
Food and Drugs Administration.pptxFood and Drugs Administration.pptx
Food and Drugs Administration.pptxAnkitsharma811886
 
Drug Use, Regulation, and the LawChapter 3Guid.docx
Drug Use, Regulation, and the LawChapter 3Guid.docxDrug Use, Regulation, and the LawChapter 3Guid.docx
Drug Use, Regulation, and the LawChapter 3Guid.docxjacksnathalie
 
History of FDA approval
History of FDA approvalHistory of FDA approval
History of FDA approvalMichael Basham
 
Kefauver Harris amendments
Kefauver Harris amendments Kefauver Harris amendments
Kefauver Harris amendments Anilkumar158740
 
Injection Eye Drug Research Paper
Injection Eye Drug Research PaperInjection Eye Drug Research Paper
Injection Eye Drug Research PaperDarlene Hernandez
 
Chapter 3 drug regulation and control
Chapter 3 drug regulation and controlChapter 3 drug regulation and control
Chapter 3 drug regulation and controlAnn Bentley
 
Gmp inspection for medicinal product
Gmp inspection for medicinal productGmp inspection for medicinal product
Gmp inspection for medicinal productFasika Alemu
 
Investaigational drugs
Investaigational drugsInvestaigational drugs
Investaigational drugsSultan Alharbi
 

Similar a Federal food, drug & cosmetics act (20)

History of Drug Aproval
History of Drug AprovalHistory of Drug Aproval
History of Drug Aproval
 
1 gmp essentials
1 gmp essentials1 gmp essentials
1 gmp essentials
 
Drug development and nda
Drug development and ndaDrug development and nda
Drug development and nda
 
73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx73What is Special Education 1iStockphotoThinkstock.docx
73What is Special Education 1iStockphotoThinkstock.docx
 
Food And Drug Administration V Brown &Amp; Williamson
Food And Drug Administration V Brown &Amp; WilliamsonFood And Drug Administration V Brown &Amp; Williamson
Food And Drug Administration V Brown &Amp; Williamson
 
Food and Drugs Administration.pptx
Food and Drugs Administration.pptxFood and Drugs Administration.pptx
Food and Drugs Administration.pptx
 
GMP Lecture 1.pptx
GMP Lecture 1.pptxGMP Lecture 1.pptx
GMP Lecture 1.pptx
 
Drug Use, Regulation, and the LawChapter 3Guid.docx
Drug Use, Regulation, and the LawChapter 3Guid.docxDrug Use, Regulation, and the LawChapter 3Guid.docx
Drug Use, Regulation, and the LawChapter 3Guid.docx
 
History of FDA approval
History of FDA approvalHistory of FDA approval
History of FDA approval
 
What is FDA?
What is FDA?What is FDA?
What is FDA?
 
History & Evolution of GMP Regulations
History & Evolution of GMP RegulationsHistory & Evolution of GMP Regulations
History & Evolution of GMP Regulations
 
Kefauver Harris amendments
Kefauver Harris amendments Kefauver Harris amendments
Kefauver Harris amendments
 
Injection Eye Drug Research Paper
Injection Eye Drug Research PaperInjection Eye Drug Research Paper
Injection Eye Drug Research Paper
 
Chapter 3 drug regulation and control
Chapter 3 drug regulation and controlChapter 3 drug regulation and control
Chapter 3 drug regulation and control
 
FDA
FDAFDA
FDA
 
Gmp inspection for medicinal product
Gmp inspection for medicinal productGmp inspection for medicinal product
Gmp inspection for medicinal product
 
hatch-waxman act@amendments
hatch-waxman act@amendmentshatch-waxman act@amendments
hatch-waxman act@amendments
 
Investaigational drugs
Investaigational drugsInvestaigational drugs
Investaigational drugs
 
Inside the FDA
Inside the FDAInside the FDA
Inside the FDA
 
History of gmp
History of gmpHistory of gmp
History of gmp
 

Más de Jamia Hamdard

Research report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentResearch report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentJamia Hamdard
 
Control of component, containers and closures
Control of component, containers and closuresControl of component, containers and closures
Control of component, containers and closuresJamia Hamdard
 
Resealed erytrocytes
Resealed erytrocytesResealed erytrocytes
Resealed erytrocytesJamia Hamdard
 
Antibodies drug delivery system
Antibodies drug delivery systemAntibodies drug delivery system
Antibodies drug delivery systemJamia Hamdard
 
Validation of solid oral dosage form, tablet 1
Validation of solid oral dosage form, tablet 1Validation of solid oral dosage form, tablet 1
Validation of solid oral dosage form, tablet 1Jamia Hamdard
 
Mucoadhesive drug delivery system
Mucoadhesive drug delivery systemMucoadhesive drug delivery system
Mucoadhesive drug delivery systemJamia Hamdard
 
Packaging designs and specifications
Packaging designs and specificationsPackaging designs and specifications
Packaging designs and specificationsJamia Hamdard
 
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSING
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSINGOPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSING
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSINGJamia Hamdard
 

Más de Jamia Hamdard (12)

Research report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatmentResearch report on small molecules in multiple myeloma treatment
Research report on small molecules in multiple myeloma treatment
 
Control of component, containers and closures
Control of component, containers and closuresControl of component, containers and closures
Control of component, containers and closures
 
Resealed erytrocytes
Resealed erytrocytesResealed erytrocytes
Resealed erytrocytes
 
Antibodies drug delivery system
Antibodies drug delivery systemAntibodies drug delivery system
Antibodies drug delivery system
 
Drying
DryingDrying
Drying
 
Nanoemulsion
NanoemulsionNanoemulsion
Nanoemulsion
 
Validation of solid oral dosage form, tablet 1
Validation of solid oral dosage form, tablet 1Validation of solid oral dosage form, tablet 1
Validation of solid oral dosage form, tablet 1
 
Mucoadhesive drug delivery system
Mucoadhesive drug delivery systemMucoadhesive drug delivery system
Mucoadhesive drug delivery system
 
Mixing muheem
Mixing muheemMixing muheem
Mixing muheem
 
Muheem on mg
Muheem on mgMuheem on mg
Muheem on mg
 
Packaging designs and specifications
Packaging designs and specificationsPackaging designs and specifications
Packaging designs and specifications
 
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSING
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSINGOPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSING
OPTIMIZATION IN PHARMACEUTICS,FORMULATION & PROCESSING
 

Último

The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsEugene Lysak
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfMohonDas
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRATanmoy Mishra
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfMohonDas
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxDr. Asif Anas
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxMYDA ANGELICA SUAN
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.EnglishCEIPdeSigeiro
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptxmary850239
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and stepobaje godwin sunday
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesMohammad Hassany
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17Celine George
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxKatherine Villaluna
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxSaurabhParmar42
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17Celine George
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational PhilosophyShuvankar Madhu
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...Nguyen Thanh Tu Collection
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptxraviapr7
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphNetziValdelomar1
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.raviapr7
 

Último (20)

The Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George WellsThe Stolen Bacillus by Herbert George Wells
The Stolen Bacillus by Herbert George Wells
 
HED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdfHED Office Sohayok Exam Question Solution 2023.pdf
HED Office Sohayok Exam Question Solution 2023.pdf
 
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRADUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
DUST OF SNOW_BY ROBERT FROST_EDITED BY_ TANMOY MISHRA
 
Diploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdfDiploma in Nursing Admission Test Question Solution 2023.pdf
Diploma in Nursing Admission Test Question Solution 2023.pdf
 
Ultra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptxUltra structure and life cycle of Plasmodium.pptx
Ultra structure and life cycle of Plasmodium.pptx
 
Patterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptxPatterns of Written Texts Across Disciplines.pptx
Patterns of Written Texts Across Disciplines.pptx
 
Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.Easter in the USA presentation by Chloe.
Easter in the USA presentation by Chloe.
 
3.21.24 The Origins of Black Power.pptx
3.21.24  The Origins of Black Power.pptx3.21.24  The Origins of Black Power.pptx
3.21.24 The Origins of Black Power.pptx
 
General views of Histopathology and step
General views of Histopathology and stepGeneral views of Histopathology and step
General views of Histopathology and step
 
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdfPersonal Resilience in Project Management 2 - TV Edit 1a.pdf
Personal Resilience in Project Management 2 - TV Edit 1a.pdf
 
Human-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming ClassesHuman-AI Co-Creation of Worked Examples for Programming Classes
Human-AI Co-Creation of Worked Examples for Programming Classes
 
How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17How to Add a many2many Relational Field in Odoo 17
How to Add a many2many Relational Field in Odoo 17
 
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptxPractical Research 1: Lesson 8 Writing the Thesis Statement.pptx
Practical Research 1: Lesson 8 Writing the Thesis Statement.pptx
 
CAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptxCAULIFLOWER BREEDING 1 Parmar pptx
CAULIFLOWER BREEDING 1 Parmar pptx
 
How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17How to Use api.constrains ( ) in Odoo 17
How to Use api.constrains ( ) in Odoo 17
 
Philosophy of Education and Educational Philosophy
Philosophy of Education  and Educational PhilosophyPhilosophy of Education  and Educational Philosophy
Philosophy of Education and Educational Philosophy
 
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
CHUYÊN ĐỀ DẠY THÊM TIẾNG ANH LỚP 11 - GLOBAL SUCCESS - NĂM HỌC 2023-2024 - HK...
 
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptxClinical Pharmacy  Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
 
Presentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a ParagraphPresentation on the Basics of Writing. Writing a Paragraph
Presentation on the Basics of Writing. Writing a Paragraph
 
Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.Drug Information Services- DIC and Sources.
Drug Information Services- DIC and Sources.
 

Federal food, drug & cosmetics act

  • 1. Federal Food, Drug & Cosmetics Act Kefauver's-Harris Amendments ABDUL MUHEEM M.PHARMA 2ND SEM. (PHARMACEUTICS) JAMIA HAMADARD muheem.abdul985@gmail.com
  • 3. OBJECTIVES OF FFDCA In United States Federal Food, Drug, and Cosmetic Act (FFDCA, FDCA, or FD&C), is a set of laws passed by Congress in 1938 giving authority to the U.S. Food and Drug Administration (FDA) to oversee the safety of food, drugs, and cosmetics.  It replaced the earlier Pure Food and Drug Act of 1906 due to Elixir Sulphanilamide disaster.  1938 Act continued the information provision requirements of the 1906 Act. The classification “misbranded” was expanded example, and now included any drug whose label failed to identify and quantify the precise ingredients, to list effects and possible side effects, and to give directions and cautionary information.  1938 Act also expanded the FDA’s powers over medical devices .
  • 5. Reason for implemented new act  1937 – sulfanilamide crisis November 16, 1937: A Senate resolution directs the U.S. Department of Agriculture to give a full accounting of the "Elixir Sulfanilamide" tragedy. The drug, containing a poisonous solvent(ethylene glycol / propylene glycol mix-up), was not safety tested and has killed 107 persons, many of them children. The incident made Congress to pass the Federal Food, Drug, and Cosmetic Act, which includes stronger drug safety requirements
  • 6. OTHER TRAGEDIES Koremlu Cream Contained Thallium acetate Serious hazardous side effects due to thallium Radiothor "Radium containing water“ Consumers died of radiation exposure Label true and no therapeutic claims
  • 7. Lack of standards for food products  Developments in Science and technology Canning / Chemical analysis  Expansion of cosmetics industry
  • 8. GOALS OF FDCA(1938)  The FDCA mandates the safety, purity, and in some cases the "effectiveness" of the products within its scope.  FDA ensures safety through inspections of products already on the market, controls the manufacturing practices of companies, and possesses recall and seizure authority.  The FDCA's Goal is to disclose information- requires truthfulness and completeness in product labeling and other marketing communications.  The act forbids "misbranding," and provides a range of civil and criminal enforcement mechanisms against inaccurate product labeling.  Section contains both civil law and criminal law clauses.  The FDCA in 1958 with the Food Additives Amendment (also called the "Delaney Clause" after its House sponsor), precluding FDA approval of any food additive found to cause cancer in humans or animals.
  • 9. Food & drug act  Prohibited the sales of adulterated &misbranded drugs.  Drug could be marketed as long as the label did not present false information regarding the strength & purity.  no requirement to disclose ingredients.  A largely unregulated industry was causing numerous public health problems.
  • 11. CHAPTER WISE DESCRIPTION: Chapter I. Short Titles Chapter II – Definitions.  201(f) is the definition for a food, which explicitly includes chewing gum  201(g) is the definition for a drug  201(h) is the definition for a medical device  201(s) is the definition of a food additive  201(ff) is the definition of a dietary supplement
  • 12. CHAPTER III. Prohibited Acts and Penalties 301. Prohibited Acts 302. Injunction proceedings 303. Penalties 304. Seizures 305. Hearing before report of criminal violation 306. Report of minor violations 307. Proceedings in name of United States; provision as to subpoenas .
  • 13. CHAPTER IV. Food 401. Definitions and standards for food 402. Adulterated food 403. Misbranded food 404. Emergency permit control 405. Regulations making exemptions 406. Tolerances for poisonous ingredients in food 407. Oleomargarine or margarine 408. Tolerances for pesticide chemicals in or on raw agricultural commodities 409. Food additives 410. Bottled drinking water 411. Vitamins and minerals 412. Requirements for Infant Formulas .
  • 14. CHAPTER V. Drugs and Devices  505 is the description of the drug approval process  510(k) is the section that allows for clearance of medical devices  515 is the description of the device approval process.
  • 15. DRUG AND DEVICES Sections in FDCA gives following information-  505 is the description of the drug approval process  510(k) is the section that allows for clearance of class II medical devices  515 is the description of the (class III) device approval process. Section 510(k) of the Federal Food, Drug, and Cosmetic Act requires those device manufacturers who must register to notify FDA, at least 90 days in advance, of their intent to market a medical device. This is known as Premarket Notification. Class I: Devices that do not require premarket approval or clearance but must follow general controls. Dental floss is a class I device. Class II: Devices that are cleared using the 510(k) process. Diagnostic tests, cardiac catheters, and amalgam alloys used to fill cavities are all class II devices. Class III: Devices that are approved by the Premarket Approval (PMA) process, analogous to a New Drug Application. These tend to be devices that are permanently implanted into a human body or may be necessary to sustain life
  • 16. CHAPTER VII : GENERAL ADMINISTRATIVE PROVISIONS 701. Regulations and hearings 702. Examinations and investigations 702a. Seafood inspection 703. Records of interstate shipment 704. Factory inspection 705. Publicity 706. Listing and certification of color additives for foods, drugs, and cosmetics.
  • 17. CHAPTER VIII : 801.Imports And Exports 8 CHAPTER IX : 901. Miscellaneous
  • 18. LIMITATIONS OF 1938,FOOD DRUG AND COSMETIC ACT INCLUDES  It did not included drugs which were previously marketed.  Drugs had to be proven safe but not proven effective.  The federal govt. had little authority to enact penalties, if the information on the labels was not written clearly.  Drugs manufacturer were given the responsibility for determining whether a drug would be sold as a prescription or over the counter drug.  Drug manufacturers conducted their own test to determine drugs effectiveness.
  • 20. Introduction  The Food and Drug Administration (FDA), established in 1938 as a part of the US Department of Health and Human Services (HHS), regulates products accounting for roughly 25% of the US gross national product.  Major concerns arose with the scandal of birth defects in European nations caused by Thalidomide, a drug to be introduced into the US.  The drug was already in use by the pregnant women in Africa and Europe from 1956-1962 and caused an estimated 10,000 children born with congenital deformitiesPhocomelia.).
  • 22. News & Implementation Of Amendments Week In FDA History - July 15,1962 Thalidomide, a newly developed sleeping pill, is found to have caused birth defects in thousands of babies born in Western Europe. News reports on the role of FDA medical officer Dr. Frances O. Kelsey in keeping the drug off the American market arouse public support for stronger drug regulation
  • 23. Week In FDA History - Oct. 10,1962  October 10, 1962: The Kefauver-Harris Drug Amendments are passed, prompted in part by public concern over birth defects caused by the drug thalidomide. Among the new requirements: proof of drug effectiveness as well as safety, controls over clinical trials, and better quality assurance practices in drug manufacturing
  • 24.  Dr. Francis Kathleen Oldham Kelsey, working for the US FDA did not want to approve thalidomide into the American drug market because it was not properly tested as a result of what was going on in those years.  The KEFAUVER HARRIS AMENDMENT was a response to the thalidomide tragedy. It was signed by President John F. Kennedy on October 10, 1962.  US senator Estes Kefauver of the state of Tennessee and Arkansas state representative Oren Harris required the American drug manufacturers to present proof of the safety and effectiveness of their drugs before any endorsements.  Hence, this amendment is also referred to as the DRUG EFFICACY AMENDMENT.
  • 26. KEFAUVER HARRIS AMENDMENT I N T Concerne Controls R over clinical O d with trials and D proof of Passed in better QA U drug 1962 practices in C effectiven drug T ess and manufacturi I safety ng O N
  • 27. Objectives Of Amendments  Efficacy was to be established for all drugs since 1938.  Required FDA to assess the efficacy as well as safety for all drugs products.  First time manufactures were required to prove effectiveness of drug products prior to marketing.  Gave FDA stricter control over clinical drug trials.  Set GMP to be followed by drug industry.  Regulated advertising.  Kefauver-Harris imposed the efficacy requirement prior to NDA approval by FDA.
  • 28. APPROVAL OF NEW DRUGS AFTER IMPLEMENTED OF AMENDMENTS  New drug: 1) safe and effective. 2) approved under NDA procedure a/c to act at section 505.  IND: for filing IND, form FD-1571,FD- 1572 and FD-1573 are filled.  NDA: Form FD-356.
  • 30. DRUG EFFICACY STUDy IMPLEMENTATION (DESI) COLLABORATION WITH NATIONAL ESTABLISHME ACADEMY OF NT OF THE SCIENCE- DESI NATIONAL PROGRAM IN RESEARCH 1968 COUNCIL (NAS- NRC) It was a retrospective efficacy assessment of drugs approved prior to 1962.
  • 31. DRUG EFFICACY STUDIES Early development In 1966, FDA commissioner approached NAS-NRC to review already marketed drugs under NDAs approved from 1938-1962. There were about 300 different medicinal agents. This was carried out by establishing review committees and a Policy Advisory Committee whose members were well acquainted with medical, legal and industrial problems of drugs. 27 and more panels were developed concerning with drugs used in allergy, anti histaminics, dermatology, anti neoplastics, etc. Guidelines were established by the advisory committee to review work of the panels. By October 1969, the review program was formerly organized and in operation. The types of products reviewed included single drug entities or products with two or more entities.
  • 32. DRUG EFFICACY STUDIES Early development The panels sought evidence of drug efficacy from four main sources: 1) Briefs submitted by the sponsor of the drug 2)Additional evidence directly solicited from the sponsor 3)The files of the FDA 4)Pertinent medical literature brought in by the panelists.
  • 33. DRUG EFFICACY STUDIES Effectiveness categories EFFECTIVE Substantial evidence of efficacy INEFFECTI VE Insufficient data supporting efficacy PROBABLY POSSIBLY EFFECTIVE EFFECTIVE Needed Research extra info, needed, max max time 12 time 6 months months
  • 34. DRUG EFFICACY STUDIES The conclusions IMMEDIATE REMOVAL OF PRODUCTS CURRENTLY MARKETED RECOGNITION OF CLINICAL STUDIES TO VERIFY OR ESTABLISH EFFECTIVENESS UNDER THE NEW LAW RECOGNITION THAT DIRECTION OR LABELLING OF CERTAIN PRODUCTS WERE POORLY ORGANIZED, OUTDATED AND ORIENTED TO PROMOTION OF PRODUCT PACKAGE INSERTS NEEDED TO BE BROUGHT UP TO MODERN STANDARDS OF ACCURATE AND OBJECTIVE DRUG INFORMATION.
  • 35. DRUG EFFICACY STUDY RECORDS The records of the Drug Efficacy Study contains:  Correspondence  reports  meeting minutes  press clippings  other records documenting the activities of the DES.
  • 36. DRUG EFFICACY STUDIES abbreviated new drug applications  One of the early effects of DESI study was the development of ANDA.  An Abbreviated New Drug Application (ANDA) is an application for a U.S. generic drug approval for an existing licensed medication or approved drug.  The ANDA is submitted to FDA's Center for Drug Evaluation and Research, Office of Generic Drugs, which provides for the review and ultimate approval of a generic drug product. Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.  A generic drug product is one that is comparable to an innovator drug product in dosage form, strength, route of administration, quality, performance characteristics and intended use. All approved products, both innovator and generic, are listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations.
  • 37. DRUG EFFICACY STUDIES abbreviated new drug applications  Generic drug applications are termed "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent (i.e., performs in the same manner as the innovator drug).  The generic version must deliver the same amount of active ingredients into a patient's bloodstream in the same amount of time as the innovator drug.  Using bioequivalence as the basis for approving generic copies of drug products was established by the Drug Price Competition and Patent Term Restoration Act of 1984, also known as the HATCH-WAXMAN ACT.  This Act expedites the availability of less costly generic drugs by permitting FDA to approve applications to market generic versions of brand-name drugs without conducting costly and duplicative clinical trials.
  • 39. FLUOROQU INOLONE THE BLACK BOX Tendonitis (8 july, REGULATION 2008)  On 12 Feb. 1972 FDA promulgated this regulation which required that the “less than effective” products should be AVANDIA notified to the practitioner’s by including a statement (anti prominently in the labeling & surrounding it with an diabetic) appropriate border. Heart attack 14 Nov, 2007  It is a type of warning that appears on the package insert DEPO for prescription drugs that may cause serious adverse PROVERA effects. It is so named for the black border that usually Loss of bone surrounds the text of the warning. density 17 Nov, 2004  It is the strongest warning that the FDA requires. CELEBREX (celecoxib) CV & GI risk 2002
  • 41. Other FDA REASSESSMENT PROJECTS  The GRAS List Review of 1969 (review of the safety of all the food ingredients that had been included on the Generally Recognized As Safe List of the late 1950s);  The OTC Drug Review of 1972 (review of the safety and efficacy of all OTC drugs; and  The Biologics Review of 1972 (review the safety and efficacy of all biologicals)
  • 43. Other related legislations The Medical Device Amendments of 1976 followed a U.S. Senate finding that faulty medical devices had caused 10,000 injuries, including 731 deaths. The law applied safety and effectiveness safeguards to new devices.
  • 44. Other related legislations 2005 Formation of the Drug Safety Board consisting of FDA staff and representatives from the National Institutes of Health and the Veterans Administration. The Board will advise the Director, Center for Drug Evaluation and Research, FDA, on drug safety issues.
  • 45. Contd… DRUG SAFETY AND DRUG EFFICACY: TWO SIDES OF THE SAME COIN In 2007, a committee of academic scientists, research advocates and representatives of patient community was convened to recommend ways in which the Congress and the FDA could further strengthen product evaluation for it’s efficacy. A similar article was also published in the AACR, in the same year.
  • 46. SAFETY AND EFFICACY MONITORING Current scenario FDA’s MedWatch program can Serious & also be unexpected approached side effects for this NDA sponsors should write to purpose. submit reports the FDA within quarterly for 15 days of first 3 yrs and receipt of info. annually afterwards.
  • 47. Impacts of Kefauver Harris Amendment(1962) • The Kefauver Harris Amendment strengthened the U.S. Food and Drug Administration's control of experimentation on humans. • It changed the way new drugs are approved and regulated. • It introduced a "proof-of-efficacy" requirement, that was not present before. • The Amendment required drug advertising to disclose accurate information about side effects and efficacy of treatments. • Cheap generic drugs could no longer be marketed as expensive drugs under new trade names as new "breakthrough" medications, as they were prior to the amendment
  • 49. DRUG EFFICACY STUDY IMPLEMENTATION The amendment made onerous to evaluate each product, also to evaluate the active ingredients in the products. The active ingredients were placed into one of the three categories. Category I drugs: those determined to be safe , effective, and properly labeled. Category II drugs: those not generally recognized as safe and effective, or recognized as mislabeled; must be removed from medications within 6 months after the FDA issues its final regulations. Category III drugs: those for which data is insufficient to determine general recognition of safety and effectiveness.
  • 50. CONCLUSION Today, the FDA regulates $1 trillion worth of products a year. It ensures the safety of all food except for meat, poultry and some egg products; ensures the safety and effectiveness of all drugs, biological products (including blood, vaccines and tissues for transplantation), medical devices, and animal drugs and feed; and makes sure that cosmetics and medical and consumer products that emit radiation do no harm.
  • 51. ConClusions … By 1984, final action had been completed on 3,443 products; - 2,225 were found to be effective, 1,051 were found not effective, and 167 were pending.
  • 52. References  http://www.absoluteastronomy.com/discussion/Drug_Efficacy_Stu dy_Implementation  http://en.wikipedia.org/wiki/Talk:Drug_Efficacy_Study_Implement ation  http://www.ssa.gov/OP_Home/comp2/B-CFR-42.html  http://www.nationalacademies.org/ The Drug Efficacy Study of the National Research Council’s Division of Medical Sciences, 1966- 1969,  W.M. WARDELL, The US Drug Efficacy Study and its Implication (DESI), Associate Professor, Pharmacology and Toxicology, University of Rochester, and Director, Center for the Study of Drug Development, USA  http://edocket.access.gpo.gov/cfr_2008/aprqtr/pdf/21cfr207.20.p df  W.E. GILBERTSON, The OCT Drug Review - FDA's Viewpoint, Director Division of OTC Drug Evaluation, Food and Drug Administration, Rockville, Maryland, USA  Julie B. Esmay, B.S., and Albert I. Wertheimer, Ph.D., A REVIEW OF OVER-THE-COUNTER DRUG THERAPY, Journal of Community Health Vol. 5, No. 1, Fall 1979,
  • 53. References  Http://www.Personalcarecouncil.Org/  Http://www.Fda.Gov/drugs/informationondrugs/default.Htm  Http://www.Fda.Gov/drugs/guidancecomplianceregulatoryin formation/drugregistrationandlisting/default.Htm  Center for veterinary medicine program policy and procedures manual, guide 1240.3560, General review and enforcement policies, responsible office: hfv-210, registration of producers of drugs and listing of drugs in commercial distribution.  Guidance for industry , providing regulatory submissions in electronic format – drug establishment registration and drug listing  Alan h. Kaplan, esq., Fifty years of drug amendments revisited: in easy-to-swallow capsule form